MRI software developer SpinTech MRI has raised $6.5 million in a series A financing round led by Level 8 Ventures and Genesis Innovation Group's Cultivate(MD) Capital Fund.
SpinTech MRI will use the funds to expand deployments of its Strategically Acquired Gradient Echo (STAGE) quantitative MRI software platform for neurologists, radiologists, and researchers, according to the vendor. STAGE, which has been implemented at Yale School of Medicine and 50 other healthcare institutions, is designed to support research, analysis, and treatment of Parkinson's disease, Alzheimer's disease, dementia, multiple sclerosis, traumatic brain injury, stroke, and cerebral microbleeds, the company said.
The software has received U.S. Food and Drug Administration 510(k) clearance for use with 1.5-tesla and 3-tesla MRI scanners from all vendors, SpinTech MRI said.
